

Pedro Berraondo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1153799/publications.pdf>

Version: 2024-02-01

156
papers

6,294
citations

109321

35
h-index

82547

72
g-index

166
all docs

166
docs citations

166
times ranked

10320
citing authors

#	ARTICLE	IF	CITATIONS
1	Cytokines in clinical cancer immunotherapy. <i>British Journal of Cancer</i> , 2019, 120, 6-15.	6.4	720
2	Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. <i>Nature Medicine</i> , 2019, 25, 470-476.	30.7	459
3	CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity. <i>Immunity</i> , 2020, 52, 856-871.e8.	14.3	387
4	Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. <i>Nature</i> , 2019, 569, 428-432.	27.8	313
5	Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs). <i>Clinical Cancer Research</i> , 2016, 22, 3924-3936.	7.0	306
6	An RNA toolbox for cancer immunotherapy. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 751-767.	46.4	171
7	Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells. <i>Immunology and Cell Biology</i> , 2017, 95, 347-355.	2.3	160
8	Targeting NK-cell checkpoints for cancer immunotherapy. <i>Current Opinion in Immunology</i> , 2017, 45, 73-81.	5.5	158
9	Low Surface Expression of B7-1 (CD80) Is an Immunoescape Mechanism of Colon Carcinoma. <i>Cancer Research</i> , 2006, 66, 2442-2450.	0.9	129
10	Systemic messenger RNA as an etiological treatment for acute intermittent porphyria. <i>Nature Medicine</i> , 2018, 24, 1899-1909.	30.7	125
11	Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: development of an FGF19-based chimeric molecule to promote fatty liver regeneration. <i>Gut</i> , 2017, 66, 1818-1828.	12.1	118
12	IL8, Neutrophils, and NETs in a Collusion against Cancer Immunity and Immunotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 2383-2393.	7.0	108
13	Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients. <i>Annals of Oncology</i> , 2018, 29, 1312-1319.	1.2	106
14	Innate immune mediators in cancer: between defense and resistance. <i>Immunological Reviews</i> , 2016, 274, 290-306.	6.0	104
15	Eradication of Large Tumors in Mice by a Tritherapy Targeting the Innate, Adaptive, and Regulatory Components of the Immune System. <i>Cancer Research</i> , 2007, 67, 8847-8855.	0.9	103
16	Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells. <i>Cancer Cell</i> , 2019, 36, 613-629.e7.	16.8	99
17	In vitro and in vivo comparative study of chimeric liver-specific promoters. <i>Molecular Therapy</i> , 2003, 7, 375-385.	8.2	97
18	Successful Colon Cancer Eradication after Chemoimmunotherapy Is Associated with Profound Phenotypic Change of Intratumoral Myeloid Cells. <i>Journal of Immunology</i> , 2011, 186, 807-815.	0.8	92

#	ARTICLE	IF	CITATIONS
19	Effect of Adeno-Associated Virus Serotype and Genomic Structure on Liver Transduction and Biodistribution in Mice of Both Genders. <i>Human Gene Therapy</i> , 2009, 20, 908-917.	2.7	88
20	Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice. <i>Gut</i> , 2011, 60, 341-349.	12.1	87
21	Messenger RNA therapy for rare genetic metabolic diseases. <i>Gut</i> , 2019, 68, 1323-1330.	12.1	76
22	Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer. <i>Journal of Hepatology</i> , 2007, 47, 807-815.	3.7	69
23	Revisiting Interleukin-12 as a Cancer Immunotherapy Agent. <i>Clinical Cancer Research</i> , 2018, 24, 2716-2718.	7.0	69
24	TGF β 2 Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 621-631.	4.1	68
25	Peptide inhibitors of transforming growth factor β 2 enhance the efficacy of antitumor immunotherapy. <i>International Journal of Cancer</i> , 2009, 125, 2614-2623.	5.1	62
26	Cellular cytotoxicity is a form of immunogenic cell death. , 2020, 8, e000325.		61
27	Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus α -Derived Vectors Fosters Dendritic Cell α -Mediated T-cell Cross-Priming. <i>Cancer Research</i> , 2018, 78, 6643-6654.	0.9	60
28	Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism. <i>Oncolmmunology</i> , 2016, 5, e1062967.	4.6	52
29	Development of a Liver-specific Tet-On Inducible System for AAV Vectors and Its Application in the Treatment of Liver Cancer. <i>Molecular Therapy</i> , 2011, 19, 1245-1253.	8.2	51
30	<i>In vivo</i> depletion of DC impairs the anti α -tumor effect of agonistic anti α -CD137 mAb. <i>European Journal of Immunology</i> , 2009, 39, 2424-2436.	2.9	47
31	Myeloid-derived cells are key targets of tumor immunotherapy. <i>Oncolmmunology</i> , 2014, 3, e28398.	4.6	47
32	Antitumor Immunotherapeutic and Toxic Properties of an HDL-Conjugated Chimeric IL-15 Fusion Protein. <i>Cancer Research</i> , 2013, 73, 139-149.	0.9	44
33	Making the Most of Cancer Surgery with Neoadjuvant Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 1312-1314.	9.4	41
34	Gene Therapy: A Pharmacokinetic/Pharmacodynamic Modelling Overview. <i>Pharmaceutical Research</i> , 2010, 27, 1487-1497.	3.5	40
35	Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine α -plasmid complex. <i>Vaccine</i> , 2005, 23, 1384-1392.	3.8	39
36	Intratumoral injection of interferon α 1 and systemic delivery of agonist anti α -CD137 monoclonal antibodies synergize for immunotherapy. <i>International Journal of Cancer</i> , 2011, 128, 105-118.	5.1	39

#	ARTICLE	IF	CITATIONS
37	Intravenous Immunoglobulin Promotes Antitumor Responses by Modulating Macrophage Polarization. <i>Journal of Immunology</i> , 2014, 193, 5181-5189.	0.8	39
38	Anchoring interferon alpha to apolipoprotein Aâ€š reduces hematological toxicity while enhancing immunostimulatory properties. <i>Hepatology</i> , 2011, 53, 1864-1873.	7.3	38
39	Interleukin-15 in Gene Therapy of Cancer. <i>Current Gene Therapy</i> , 2013, 13, 15-30.	2.0	37
40	Novel strategies exploiting interleukin-12 in cancer immunotherapy. , 2022, 239, 108189.		35
41	Treatment of Chronic Viral Hepatitis in Woodchucks by Prolonged Intrahepatic Expression of Interleukin-12. <i>Journal of Virology</i> , 2009, 83, 2663-2674.	3.4	34
42	Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin. <i>International Journal of Cancer</i> , 2012, 131, 641-651.	5.1	34
43	Bile acids, FGF15/19 and liver regeneration: From mechanisms to clinical applications. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1326-1334.	3.8	34
44	Protection against Woodchuck Hepatitis Virus (WHV) Infection by Gene Gun Coimmunization with WHV Core and Interleukin-12. <i>Journal of Virology</i> , 2001, 75, 9068-9076.	3.4	32
45	Emerging therapies for acute intermittent porphyria. <i>Expert Reviews in Molecular Medicine</i> , 2016, 18, e17.	3.9	32
46	Differential Interleukinâ€š8 thresholds for chemotaxis and netosis in human neutrophils. <i>European Journal of Immunology</i> , 2021, 51, 2274-2280.	2.9	32
47	IFN-± gene therapy for woodchuck hepatitis with adeno-associated virus: differences in duration of gene expression and antiviral activity using intraportal or intramuscular routes. <i>Molecular Therapy</i> , 2005, 12, 68-76.	8.2	31
48	Intrahepatic injection of adenovirus reduces inflammation and increases gene transfer and therapeutic effect in mice. <i>Hepatology</i> , 2006, 44, 623-632.	7.3	31
49	Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer: NEODURVARIB Trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 542-542.	1.6	30
50	Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion. <i>Frontiers in Immunology</i> , 2020, 11, 7.	4.8	29
51	Repurposing the yellow fever vaccine for intratumoral immunotherapy. <i>EMBO Molecular Medicine</i> , 2020, 12, e10375.	6.9	28
52	Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model. <i>Journal of Nanobiotechnology</i> , 2021, 19, 102.	9.1	27
53	Intrahepatic Injection of Recombinant Adeno-Associated Virus Serotype 2 Overcomes Gender-Related Differences in Liver Transduction. <i>Human Gene Therapy</i> , 2006, 17, 601-610.	2.7	26
54	Upregulation of natural killer cells functions underlies the efficacy of intratumorally injected dendritic cells engineered to produce interleukin-12. <i>Experimental Hematology</i> , 2002, 30, 195-204.	0.4	25

#	ARTICLE	IF	CITATIONS
55	Mathematical Model Approach to Describe Tumour Response in Mice After Vaccine Administration and its Applicability to Immune-Stimulatory Cytokine-Based Strategies. <i>AAPS Journal</i> , 2013, 15, 797-807.	4.4	24
56	Human CD8 T cells are susceptible to TNF-mediated activation-induced cell death. <i>Theranostics</i> , 2020, 10, 4481-4489.	10.0	24
57	Antitumoral efficacy of DNA nanoparticles in murine models of lung cancer and pulmonary metastasis. <i>Cancer Gene Therapy</i> , 2010, 17, 20-27.	4.6	23
58	Exploiting scavenger receptors in cancer immunotherapy: Lessons from CD5 and SR β 1. <i>European Journal of Immunology</i> , 2017, 47, 1108-1118.	2.9	23
59	Immune Desertic Landscapes in Hepatocellular Carcinoma Shaped by β -Catenin Activation. <i>Cancer Discovery</i> , 2019, 9, 1003-1005.	9.4	23
60	Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy. , 2021, 9, e002953.		23
61	CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation. <i>Nature Communications</i> , 2021, 12, 7296.	12.8	22
62	Eradication of Liver-Implanted Tumors by Semliki Forest Virus Expressing IL-12 Requires Efficient Long-Term Immune Responses. <i>Journal of Immunology</i> , 2013, 190, 2994-3004.	0.8	21
63	Liver-directed gene therapy of chronic hepadnavirus infection using interferon alpha tethered to apolipoprotein A-I. <i>Journal of Hepatology</i> , 2015, 63, 329-336.	3.7	21
64	Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15. <i>Oncolmmunology</i> , 2018, 7, e1393597.	4.6	20
65	Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells. <i>Oncolmmunology</i> , 2019, 8, e1599636.	4.6	20
66	Advances in Interleukin-12 Gene Therapy for Acquired Liver Diseases. <i>Current Gene Therapy</i> , 2009, 9, 62-71.	2.0	19
67	A Semliki Forest virus vector engineered to express IFN β induces efficient elimination of established tumors. <i>Gene Therapy</i> , 2012, 19, 271-278.	4.5	19
68	Modeling Tumor Response after Combined Administration of Different Immune-Stimulatory Agents. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 346, 432-442.	2.5	19
69	Charting roadmaps towards novel and safe synergistic immunotherapy combinations. <i>Nature Cancer</i> , 2022, 3, 665-680.	13.2	18
70	Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial?. <i>Immunotherapy</i> , 2009, 1, 845-853.	2.0	17
71	Cellular immunotherapies for cancer. <i>Oncolmmunology</i> , 2017, 6, e1306619.	4.6	17
72	Engineered fibroblast growth factor 19 protects from acetaminophen-induced liver injury and stimulates aged liver regeneration in mice. <i>Cell Death and Disease</i> , 2017, 8, e3083-e3083.	6.3	17

#	ARTICLE	IF	CITATIONS
73	A new immune-nanoplatform for promoting adaptive antitumor immune response. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 17, 13-25.	3.3	17
74	Advances in mRNA-based drug discovery in cancer immunotherapy. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 41-53.	5.0	17
75	Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity. <i>Cell Stress</i> , 2019, 3, 236-239.	3.2	17
76	The Fusion Protein of IFN- γ and Apolipoprotein A-I Crosses the Blood-Brain Barrier by a Saturable Transport Mechanism. <i>Journal of Immunology</i> , 2012, 188, 3988-3992.	0.8	16
77	Liver Gene Transfer of Interleukin-15 Constructs That Become Part of Circulating High Density Lipoproteins for Immunotherapy. <i>PLoS ONE</i> , 2012, 7, e52370.	2.5	16
78	New trends in antitumor vaccines in melanoma. <i>Annals of Translational Medicine</i> , 2017, 5, 384-384.	1.7	16
79	A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNF- α , and IL-1 β . <i>Cancer Discovery</i> , 2022, 12, 2140-2157.	9.4	16
80	CD137 Costimulation Counteracts TGF β Inhibition of NK-cell Antitumor Function. <i>Cancer Immunology Research</i> , 2021, 9, 1476-1490.	3.4	15
81	Semi-mechanistic pharmacodynamic modelling of gene expression and silencing processes. <i>European Journal of Pharmaceutical Sciences</i> , 2009, 37, 418-426.	4.0	14
82	Scavenger receptor class B, type I: a promising immunotherapy target. <i>Immunotherapy</i> , 2011, 3, 395-406.	2.0	14
83	Immunological Landscape and Clinical Management of Rectal Cancer. <i>Frontiers in Immunology</i> , 2016, 7, 61.	4.8	14
84	An Inducible Promoter Responsive to Different Porphyrinogenic Stimuli Improves Gene Therapy Vectors for Acute Intermittent Porphyria. <i>Human Gene Therapy</i> , 2018, 29, 480-491.	2.7	14
85	Bioengineered PBGD variant improves the therapeutic index of gene therapy vectors for acute intermittent porphyria. <i>Human Molecular Genetics</i> , 2018, 27, 3688-3696.	2.9	14
86	High Prevalence of Insulin Resistance in Asymptomatic Patients with Acute Intermittent Porphyria and Liver-Targeted Insulin as a Novel Therapeutic Approach. <i>Biomedicines</i> , 2021, 9, 255.	3.2	14
87	Harnessing High Density Lipoproteins to Block Transforming Growth Factor Beta and to Inhibit the Growth of Liver Tumor Metastases. <i>PLoS ONE</i> , 2014, 9, e96799.	2.5	12
88	Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory. , 2021, 9, e001586.		12
89	Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications. <i>Cancers</i> , 2021, 13, 963.	3.7	12
90	Anti-TGF β (Transforming Growth Factor β) Therapy With Betaglycan-Derived P144 Peptide Gene Delivery Prevents the Formation of Aortic Aneurysm in a Mouse Model of Marfan Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, e440-e452.	2.4	12

#	ARTICLE	IF	CITATIONS
91	Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms. <i>Cellular and Molecular Immunology</i> , 2020, 17, 576-586.	10.5	12
92	The woodchuck interferon- β system: Cloning, family description, and biologic activity. <i>Journal of Medical Virology</i> , 2002, 68, 424-432.	5.0	11
93	Characterization of high-capacity adenovirus production by the quantitative real-time polymerase chain reaction: a comparative study of different titration methods. <i>Journal of Gene Medicine</i> , 2008, 10, 1092-1101.	2.8	11
94	Immunotherapy Moves to the Early-Stage Setting in Non-Small Cell Lung Cancer: Emerging Evidence and the Role of Biomarkers. <i>Cancers</i> , 2020, 12, 3459.	3.7	11
95	761P Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer. NEODURVARIB trial. <i>Annals of Oncology</i> , 2020, 31, S589.	1.2	11
96	Immunochemotherapy against colon cancer by gene transfer of interleukin-12 in combination with oxaliplatin. <i>Onc Immunology</i> , 2012, 1, 97-99.	4.6	10
97	Interferon alpha bioactivity critically depends on Scavenger receptor class B type I function. <i>Onc Immunology</i> , 2016, 5, e1196309.	4.6	10
98	Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors. , 2021, 9, e001587.		10
99	Antitumor effect of an adeno-associated virus expressing apolipoprotein A-1 fused to interferon alpha in an interferon alpha-resistant murine tumor model. <i>Oncotarget</i> , 2017, 8, 5247-5255.	1.8	10
100	Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model. <i>Oncotarget</i> , 2016, 7, 76891-76901.	1.8	9
101	Recombinant porphobilinogen deaminase targeted to the liver corrects enzymopenia in a mouse model of acute intermittent porphyria. <i>Science Translational Medicine</i> , 2022, 14, eabc0700.	12.4	9
102	Chronic exposure to IFN α drives medullar lymphopoiesis towards T cell differentiation in mice. <i>Haematologica</i> , 2015, 100, 1014-22.	3.5	8
103	Mechanisms of action for different checkpoint inhibitors. <i>HemaSphere</i> , 2019, 3, 28-30.	2.7	8
104	Interleukin-12 Message in a Bottle. <i>Clinical Cancer Research</i> , 2020, 26, 6080-6082.	7.0	8
105	Overcoming the limitations of cytokines to improve cancer therapy. <i>International Review of Cell and Molecular Biology</i> , 2022, , 107-141.	3.2	7
106	Colon cancer eradication after chemoimmunotherapy is associated with intratumoral emergence of proinflammatory myeloid cells. <i>Onc Immunology</i> , 2012, 1, 118-120.	4.6	6
107	Overexpression of apolipoprotein A-I fused to an anti-transforming growth factor beta peptide modulates the tumorigenicity and immunogenicity of mouse colon cancer cells. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 717-725.	4.2	6
108	Cancer Immunosurveillance Caught in the Act. <i>Immunity</i> , 2016, 44, 525-526.	14.3	6

#	ARTICLE	IF	CITATIONS
109	Epistatic Oncogenic Interactions Determine Cancer Susceptibility to Immunotherapy. <i>Cancer Discovery</i> , 2018, 8, 794-796.	9.4	6
110	Treatment of Experimental Autoimmune Encephalomyelitis by Sustained Delivery of Low-Dose IFN- β . <i>Journal of Immunology</i> , 2019, 203, 696-704.	0.8	6
111	Woodchuck dendritic cells generated from peripheral blood mononuclear cells and transduced with recombinant human adenovirus serotype 5 induce antigen-specific cellular immune responses. <i>Journal of Medical Virology</i> , 2007, 79, 522-529.	5.0	5
112	Characterization of woodchuck apolipoprotein A-II: A new tool for drug delivery and identification of altered isoforms in the woodchuck chronic hepatitis model. <i>Journal of Medical Virology</i> , 2011, 83, 1221-1229.	5.0	5
113	Cytokines for the treatment of gastrointestinal cancers: clinical experience and new perspectives. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 827-841.	4.1	5
114	Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and β -PD-1. <i>British Journal of Cancer</i> , 2021, 124, 1275-1285.	6.4	5
115	Messenger RNA as a personalized therapy: The moment of truth for rare metabolic diseases. <i>International Review of Cell and Molecular Biology</i> , 2022, , .	3.2	5
116	Target-Mediated Disposition Model Describing the Dynamics of IL12 and IFN- β after Administration of a Mifepristone-Inducible Adenoviral Vector for IL-12 Expression in Mice. <i>AAPS Journal</i> , 2013, 15, 183-194.	4.4	4
117	Immunostimulatory Monoclonal Antibodies and Immunomodulation: Harvesting the Crop. <i>Cancer Research</i> , 2016, 76, 2863-2867.	0.9	4
118	Commentary on Pharmacometrics for Immunotherapy. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 8-10.	2.5	4
119	Rapid isolation and enrichment of mouse NK cells for experimental purposes. <i>Methods in Enzymology</i> , 2020, 631, 257-275.	1.0	4
120	Insulin Fused to Apolipoprotein A-I Reduces Body Weight and Steatosis in DB/DB Mice. <i>Frontiers in Pharmacology</i> , 2020, 11, 591293.	3.5	4
121	How can chemoimmunotherapy best be used for the treatment of colon cancer?. <i>Immunotherapy</i> , 2012, 4, 1787-1790.	2.0	3
122	High-density lipoproteins delivering interleukin-15. <i>Oncolmmunology</i> , 2013, 2, e23410.	4.6	3
123	Production and use of adeno-associated virus vectors as tools for cancer immunotherapy. <i>Methods in Enzymology</i> , 2020, 635, 185-203.	1.0	3
124	Firefighters for the Wrong Type of Inflammation in Tumors. <i>Cancer Discovery</i> , 2021, 11, 2372-2374.	9.4	3
125	Comprehensive molecular characterization of muscle-invasive bladder cancer (MIBC) treated with durvalumab plus olaparib in the neoadjuvant setting: Neodurvarib trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 546-546.	1.6	3
126	Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis. <i>Oncolmmunology</i> , 2022, 11, .	4.6	3

#	ARTICLE	IF	CITATIONS
127	Development of a New Hepatoprotective and Proregenerative Molecule Based on Fibroblast Growth Factor 15/19. <i>Journal of Hepatology</i> , 2016, 64, S184.	3.7	2
128	Long-Term Liver Expression of an Apolipoprotein A-I Mimetic Peptide Attenuates Interferon-Alpha-Induced Inflammation and Promotes Antiviral Activity. <i>Frontiers in Immunology</i> , 2020, 11, 620283.	4.8	2
129	Interim analysis of a phase II study of nivolumab combined with ipilimumab in patients with pediatric solid tumors in adulthood (GETHIO21).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2613-2613.	1.6	2
130	Kinetic and Dynamic Computational Model-Based Characterization of New Proteins in Mice: Application to Interferon Alpha Linked to Apolipoprotein A-I. <i>PLoS ONE</i> , 2012, 7, e42100.	2.5	2
131	Semi-Mechanistic Model for the Antitumor Response of a Combination Cocktail of Immuno-Modulators in Non-Inflamed (Cold) Tumors. <i>Cancers</i> , 2021, 13, 5049.	3.7	2
132	Production of Recombinant Woodchuck IFN α and Development of Monoclonal Antibodies. <i>Journal of Interferon and Cytokine Research</i> , 2009, 29, 75-82.	1.2	1
133	1069P A multicenter phase II study of nivolumab combined with ipilimumab in patients with pediatric solid tumours in adulthood (GETHIO21). <i>Annals of Oncology</i> , 2020, 31, S727.	1.2	1
134	Scavenger Receptor Class B Type I is Required for ^{25}OH -Vitamin D $_3$ Cellular Uptake and Signaling in Myeloid Cells. <i>Molecular Nutrition and Food Research</i> , 2020, 64, e1901213.	3.3	1
135	Premortem Tumor Stress in Radioimmunotherapy. <i>Trends in Cancer</i> , 2020, 6, 173-174.	7.4	1
136	Generation and characterization of novel co-stimulatory anti-mouse TNFR2 antibodies. <i>Journal of Immunological Methods</i> , 2021, 499, 113173.	1.4	1
137	Abstract 1698: Cellular cytotoxicity is a form of immunogenic cell death. <i>Cancer Research</i> , 2020, 80, 1698-1698.	0.9	1
138	4-1BB (CD137) in anticancer chimeras. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	1
139	A human IgE bispecific antibody shows potent cytotoxic capacity mediated by monocytes. <i>Journal of Biological Chemistry</i> , 2022, 298, 102153.	3.4	1
140	The woodchuck interferon alpha system: cloning, family description and biologic activity. <i>Journal of Hepatology</i> , 2002, 36, 180-181.	3.7	0
141	319. Improvement of Transgene Expression through the Direct Intrahepatic Injection of Adenoviral Vectors. <i>Molecular Therapy</i> , 2004, 9, S121.	8.2	0
142	350 Gene therapy for chronic hepatitis in the woodchuck model using recombinant adeno-associated virus expressing interferon alpha. <i>Journal of Hepatology</i> , 2004, 40, 106.	3.7	0
143	CS18-5. Bounding interferon alpha to apolipoprotein a-i: A strategy to reduce hematological toxicity while enhancing immunostimulatory properties. <i>Cytokine</i> , 2011, 56, 110.	3.2	0
144	Efficacy of systemic messenger RNA therapy to treat and prevent porphyria attacks in animal models of acute intermittent porphyria. <i>Molecular Genetics and Metabolism</i> , 2018, 123, S70-S71.	1.1	0

#	ARTICLE	IF	CITATIONS
145	International Symposium: Trailblazing in Cancer Immunotherapy, October 29–31, 2017, Pamplona, Spain. Cancer Immunology, Immunotherapy, 2018, 67, 1809-1813.	4.2	0
146	Abstract 1691: CD137 (4-1BB) costimulation of CD8 T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation. , 2021, , .		0
147	Intrahepatic Injection of Recombinant Adeno-Associated Virus Serotype 2 Overcomes Gender-Related Differences in Liver Transduction. Human Gene Therapy, 2006, .	2.7	0
148	Interleukin-15 in Gene Therapy of Cancer. Current Gene Therapy, 2012, 13, 15-30.	2.0	0
149	Abstract 1223: Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein.. , 2013, , .		0
150	A multicenter phase 2 study of nivolumab combined with ipilimumab in patients with pediatric solid tumors in adulthood (GETHI021).. Journal of Clinical Oncology, 2018, 36, TPS3123-TPS3123.	1.6	0
151	Abstract LB-151: Prophylactic TNF± blockade unplugs toxicity and efficacy in immunotherapy anti-PD-1 + anti-CTLA-4 combinations. , 2018, , .		0
152	Abstract 1474: Repurposing the yellow fever vaccine for intratumoral immunotherapy. , 2019, , .		0
153	Abstract 2331: Intratumor adoptive transfer of IL-12 mRNA transiently engineered anti-tumor CD8+ T cells. , 2019, , .		0
154	Abstract 1474: Repurposing the yellow fever vaccine for intratumoral immunotherapy. , 2019, , .		0
155	Abstract 2331: Intratumor adoptive transfer of IL-12 mRNA transiently engineered anti-tumor CD8+ T cells. , 2019, , .		0
156	Revisiting Intracavitary Immunotherapy of Cancer. Clinical Cancer Research, 2022, 28, 1993-1995.	7.0	0